Reviewing LianBio (NASDAQ:LIAN) and RayzeBio (NASDAQ:RYZB)

RayzeBio (NASDAQ:RYZB) and LianBio (NASDAQ:LIAN) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.

Valuation and Earnings

This table compares RayzeBio and LianBio’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
RayzeBio	N/A	N/A	-$68.60 million	N/A	N/A
LianBio	N/A	N/A	-$110.29 million	($0.81)	-0.38

Analyst Ratings

This is a breakdown of recent recommendations and price targets for RayzeBio and LianBio, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
RayzeBio	0	1	4	0	2.80
LianBio	1	1	1	0	2.00

RayzeBio presently has a consensus target price of $31.33, indicating a potential downside of 49.86%. LianBio has a consensus target price of $5.33, indicating a potential upside of 1,642.07%. Given LianBio’s higher possible upside, analysts plainly believe LianBio is more favorable than RayzeBio.

Insider and Institutional Ownership

74.8% of LianBio shares are held by institutional investors. 7.6% of LianBio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares RayzeBio and LianBio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
RayzeBio	N/A	N/A	N/A
LianBio	N/A	-33.17%	-30.19%

Summary

RayzeBio beats LianBio on 5 of the 8 factors compared between the two stocks.

About RayzeBio

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.